Integrated Attachment Theory
NCT07922382, Not applicable, Not yet recruiting, Boston University Charles River Campus
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Integrated Attachment Theory | ClinicalTrials.gov |
| NCT number | NCT07922382 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 24 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Boston University Charles River Campus | ClinicalTrials.gov |
| Conditions | Attachment Disorder | ClinicalTrials.gov |
| Interventions | IAT | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Feasibility of IAT intervention | baseline through 12 weeks | Feasibility will be assessed using intervention and study completion. The number and percentage of participants assigned to IAT who complete the 12-week IAT program and the corresponding post-intervention research assessment will be calculated. Higher completion/retention rates will indicate greater feasibility. | ClinicalTrials.gov |
| Primary | Change in attachment | baseline and 12 weeks | Attachment will be assessed using the self-report Personal Development School (PDS) Attachment-Style Questionnaire administered at baseline and again at the post-intervention assessment. The questionnaire characterizes participants' attachment patterns, including secure and insecure attachment styles. Change from baseline to 12 weeks will be evaluated, with movement toward greater attachment security interpreted as improvement. | ClinicalTrials.gov |
| Secondary | Change in emotion regulation, measured by the Difficulties in Emotion Regulation Scale (DERS-36) | baseline and 12 weeks | Emotion regulation will be assessed using the 36-item self-report Difficulties in Emotion Regulation Scale (DERS-36). Items are rated on a 5-point scale from 1 (almost never) to 5 (almost always). The total score ranges from 36 to 180. Higher scores indicate greater difficulties with emotion regulation; therefore, a decrease in score from baseline indicates improvement in emotion regulation. | ClinicalTrials.gov |
| Secondary | Change in interpersonal functioning, measured by the Inventory of Interpersonal Problems-32 (IIP-32) | baseline and 12 weeks | Interpersonal functioning will be assessed using the 32-item self-report Inventory of Interpersonal Problems, Short Form (IIP-32). Items are rated from 0 (not at all) to 4 (very much) and assess difficulties across eight interpersonal domains. Higher scores indicate greater interpersonal difficulties; therefore, a decrease from baseline indicates improvement in interpersonal functioning. | ClinicalTrials.gov |
| Secondary | Change in well-being, measured by the WHO-5 Well-Being Index | baseline and 12 weeks | Well-being will be assessed using the 5-item self-report World Health Organization 5 (WHO-5) Well-Being Index. Each item is rated from 0 to 5. Raw scores range from 0 to 25 and are multiplied by 4 to yield a score from 0 to 100. Higher scores indicate better well-being; therefore, an increase from baseline indicates improvement. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)